IL146162A0 - Macrolide compounds for the treatment of dry eye - Google Patents

Macrolide compounds for the treatment of dry eye

Info

Publication number
IL146162A0
IL146162A0 IL14616200A IL14616200A IL146162A0 IL 146162 A0 IL146162 A0 IL 146162A0 IL 14616200 A IL14616200 A IL 14616200A IL 14616200 A IL14616200 A IL 14616200A IL 146162 A0 IL146162 A0 IL 146162A0
Authority
IL
Israel
Prior art keywords
treatment
dry eye
macrolide compounds
macrolide
compounds
Prior art date
Application number
IL14616200A
Other languages
English (en)
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146162(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of IL146162A0 publication Critical patent/IL146162A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
IL14616200A 1999-04-30 2000-04-26 Macrolide compounds for the treatment of dry eye IL146162A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13200999P 1999-04-30 1999-04-30
PCT/JP2000/002756 WO2000066122A1 (en) 1999-04-30 2000-04-26 Use of macrolide compounds for the treatment of dry eye

Publications (1)

Publication Number Publication Date
IL146162A0 true IL146162A0 (en) 2002-07-25

Family

ID=22452015

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14616200A IL146162A0 (en) 1999-04-30 2000-04-26 Macrolide compounds for the treatment of dry eye

Country Status (23)

Country Link
EP (1) EP1173177B2 (de)
JP (2) JP5036934B2 (de)
KR (1) KR20020015316A (de)
CN (1) CN1190194C (de)
AR (1) AR023807A1 (de)
AT (1) ATE281167T1 (de)
AU (1) AU777915B2 (de)
BR (1) BR0011225A (de)
CA (1) CA2372448A1 (de)
CZ (1) CZ20013769A3 (de)
DE (1) DE60015516T2 (de)
ES (1) ES2232439T3 (de)
HK (2) HK1046099A1 (de)
HU (1) HUP0200864A3 (de)
IL (1) IL146162A0 (de)
MX (1) MXPA01010988A (de)
NO (1) NO20015288D0 (de)
NZ (1) NZ515339A (de)
PT (1) PT1173177E (de)
TR (1) TR200103119T2 (de)
TW (1) TWI230066B (de)
WO (1) WO2000066122A1 (de)
ZA (1) ZA200108905B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1046099A1 (zh) * 1999-04-30 2002-12-27 苏坎波公司 用於治疗乾眼的大环内酯化合物的应用
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
JP2005502621A (ja) 2001-07-06 2005-01-27 スキャンポ アーゲー インターロイキン２阻害剤および抗菌剤を含む局所投与用組成物
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
EP1536793A1 (de) * 2002-08-09 2005-06-08 Sucampo Pharmaceuticals, Inc. Ophthalmische zusammensetzungen enthaltend derivative von fk506 und deren verwendung in der behandlung von augenallergien
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AR042890A1 (es) * 2003-01-16 2005-07-06 Sucampo Pharmaceuticals Inc Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CN1882338A (zh) 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
WO2005032534A1 (ja) 2003-10-06 2005-04-14 Ophtecs Corporation 涙液異常の治療のための眼科用組成物
HUE027352T2 (en) 2005-02-09 2016-09-28 Santen Pharmaceutical Co Ltd Liquid formulations for the treatment of diseases or conditions
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
EP2335735A1 (de) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmazeutische Zusammensetzung zur Behandlung von trockenem Auge
EP3630042A4 (de) * 2017-05-30 2021-06-23 Eximore Ltd. Zusammensetzungen und verfahren zur behandlung von trockenem auge mittels freisetzung von antibiotischem macrolid
WO2019060696A1 (en) 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
EP3902525A4 (de) 2018-12-27 2022-09-28 Surface Ophthalmics, Inc. Ophthalmische pharmazeutische zusammensetzungen und verfahren zur behandlung von augenoberflächenerkrankungen
WO2022240598A1 (en) 2021-05-10 2022-11-17 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0163035B1 (ko) * 1989-07-05 1998-12-01 후지사와 도모키치로 외용 수성 액체 조성물
CA2102241C (en) * 1991-04-26 2003-12-30 Manabu Mochizuki Use of macrolide compounds for eye diseases
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
EP1067926A2 (de) * 1998-04-06 2001-01-17 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive imidazolverbindungen und deren kombinationspräparate mit tacrolimus oder cyclosporinen
AR018330A1 (es) * 1998-04-27 2001-11-14 Fujisawa Pharmaceutical Co Composiciones farmaceuticas que comprenden macrolidos como agentes activos para la terapia y profilaxis de las enfermedades de la piel
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
HK1046099A1 (zh) * 1999-04-30 2002-12-27 苏坎波公司 用於治疗乾眼的大环内酯化合物的应用

Also Published As

Publication number Publication date
DE60015516T2 (de) 2005-12-01
JP2012116857A (ja) 2012-06-21
PT1173177E (pt) 2005-03-31
KR20020015316A (ko) 2002-02-27
NO20015288L (no) 2001-10-29
NO20015288D0 (no) 2001-10-29
HUP0200864A3 (en) 2004-07-28
JP2002543132A (ja) 2002-12-17
ZA200108905B (en) 2002-12-24
AR023807A1 (es) 2002-09-04
EP1173177A1 (de) 2002-01-23
DE60015516D1 (de) 2004-12-09
EP1173177B1 (de) 2004-11-03
MXPA01010988A (es) 2004-04-21
ATE281167T1 (de) 2004-11-15
TWI230066B (en) 2005-04-01
NZ515339A (en) 2004-02-27
HUP0200864A2 (hu) 2002-07-29
AU4142900A (en) 2000-11-17
WO2000066122A1 (en) 2000-11-09
HK1046099A1 (zh) 2002-12-27
ES2232439T3 (es) 2005-06-01
TR200103119T2 (tr) 2002-04-22
CN1190194C (zh) 2005-02-23
HK1043321A1 (en) 2002-09-13
CZ20013769A3 (cs) 2002-03-13
AU777915B2 (en) 2004-11-04
JP5036934B2 (ja) 2012-09-26
EP1173177B2 (de) 2014-03-05
BR0011225A (pt) 2002-03-19
CA2372448A1 (en) 2000-11-09
CN1353608A (zh) 2002-06-12
HK1043321B (en) 2005-07-15

Similar Documents

Publication Publication Date Title
IL146162A0 (en) Macrolide compounds for the treatment of dry eye
HRP20020253A2 (en) Compounds for the treatment of ischemia
DK1117401T3 (da) Antibiotisk præparat til øjenbehandling
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB9900150D0 (en) Treatment for fabrics
GB9925136D0 (en) Novel treatment
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL144186A0 (en) Novel treatment
IL133760A0 (en) Composition for the treatment of dandruff
GB9900151D0 (en) Treatment for fabrics
GB2363604B (en) S-nitrosothiols as agents for the treatment of circulatory dsyfunctions
GB9904252D0 (en) Composition for the treatment of pain
GB9927504D0 (en) Fabric treatment
GB9926985D0 (en) Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and-cyanamides for the treatment of diseases
GB0206401D0 (en) Side effects treatment
GB9900149D0 (en) Treatment for fabrics
GB9919126D0 (en) Glaucoma treatment
GB9925550D0 (en) Glaucoma treatment
GB9908993D0 (en) Treatment
AU2002328886A1 (en) Insert for the treatment of dry eye
AUPQ282499A0 (en) Treatment of fabric
GB9920788D0 (en) Novel treatment
GB9920787D0 (en) Novel treatment